Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturers, Compounders Clash As FDA Prepares Final Offer On Office Compounding

Executive Summary

Pharmaceutical manufacturers and compounders are in opposition over the US FDA’s plans to carve out a place for pharmacies that want to keep physicians’ offices stocked with small amounts of product. Who will the agency disappoint this time?

Advertisement

Related Content

FDA Ups Pressure On Stem Cell Therapy Makers To Follow Product Approval Rules
FDA’s Revised Draft For Compounding Pharmacies Opens Door To Compounding For Office Use
Survey Shows Drug Makers Don't Expect To Begin Serializing All Packages By November Deadline
Risk and Reward: Pharmacy Compounding of Clinical Materials
NECC Crisis Festered in Ambiguity That Reigns Over Compounding

Topics

Advertisement
UsernamePublicRestriction

Register

PS124869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel